AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

FEops HEARTguide™ Receives CE Mark

April 1, 2019

GENT, Belgium--(BUSINESS WIRE)--Apr 1, 2019--FEops, a leader in personalized predictive planning for structural heart interventions, today announced that FEops HEARTguide TM has received CE mark approval. FEops HEARTguide TM is a one-in-its-kind procedure planning environment for structural heart interventions that provides physicians unique insights to evaluate device sizing and positioning pre-operatively using novel computational modeling and simulation technology. The current release includes workflows for transcatheter aortic valve implantation ( TAVI ) and left atrial appendage occlusion ( LAAO ) procedures.

FEops HEARTguide TM helps to assess the risk of potential complications by pre-operatively simulating multiple treatment scenario’s in terms of device sizing and positioning, both for TAVI and LAAO. Within the TAVI workflow it’s also possible to plan TAVI procedures for patients suffering from bicuspid aortic valve stenosis which incidence is increasing with the shift towards treating low-risk patients.

Feedback from some of the pioneers that have been evaluating FEops HEARTguide TM is very encouraging. Dr Cameron Dowling (St George’s Hospital, London, UK) stated “FEops HEARTguide TM gives our team increased confidence to perform TAVI in the most challenging of aortic valve anatomies”. In addition, Dr Ole De Backer (Rigshospitalet, Copenhagen, Denmark) echoed “I have the strong hope and believe that preprocedural planning with  FEops HEARTguideTM  will transform  percutaneous LAA closure  into an even  more safe  and  more efficient  procedure for patients with non-valvular atrial fibrillation and contraindications for oral anticoagulant therapy.”

“I am extremely proud of the whole FEops team for reaching this important regulatory and commercial milestone and very pleased that we can offer our unique pre-operative planning support to the European clinical community” said Matthieu De Beule, CEO FEops. The European launch of FEops HEARTguide TM is a crucial next step to embody FEops’ vision to become the game-changer in the way transcatheter structural heart devices are designed and procedures are planned in the future.

FEops HEARTguide TM cloud-based procedure planning environment uses advanced personalized computational modeling and simulation to provide clinicians and medical device manufacturers with first-ever insights into the interaction between transcatheter structural heart devices and specific patient anatomy – preoperatively. The current release includes TAVI and LAAO workflows. Such insights have the power to accelerate research and development of novel device-based solutions, as well as ultimately help to improve clinical outcomes in real-world hospital settings.

About FEops

Privately held FEops, headquartered in Gent, Belgium, is a leader in personalized predictive planning for structural heart interventions. In September 2017, FEops announced that it closed a 6 million euros financing, led by Valiance, and joined by existing investors Capricorn Venture Partners and PMV.

www.feops.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20190401005867/en/

CONTACT: Press

Matthieu De Beule, PhD

CEO

Tel: 00 32 9 292 80 30

Email:matthieu.debeule@feops.com

KEYWORD: BELGIUM EUROPE

INDUSTRY KEYWORD: TECHNOLOGY SOFTWARE HEALTH BIOTECHNOLOGY CARDIOLOGY HOSPITALS MEDICAL DEVICES

SOURCE: FEops

Copyright Business Wire 2019.

PUB: 04/01/2019 04:18 PM/DISC: 04/01/2019 04:18 PM

http://www.businesswire.com/news/home/20190401005867/en

All contents © copyright 2019 The Associated Press. All rights reserved.